TITLE

Pipeline

PUB. DATE
December 2011
SOURCE
Pharmaceutical Representative;Dec2011, Vol. 41 Issue 12, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG have initiated a clinical trial on the efficacy and safety of the drug Eylea. Cara Therapeutics Inc. has initiated a first phase clinical trial of its peptide-based drug CR-845. Cleveland Clinic Foundation has successfully conducted a clinical trial for the drug Resverlogix.
ACCESSION #
69647451

 

Related Articles

  • In Brief.  // Ophthalmology Times;9/1/2007, Vol. 32 Issue 17, p6 

    The article offers news briefs related to ophthalmology. The Ministry of Health, Labor, and Welfare in Japan has approved travoprost ophthalmic solution 0.004% for the treatment of glaucoma and ocular hypertension. The first ophthalmology training center has opened in Cicendo Hospital, Bandung,...

  • Regeneron, Bayer Expanding Phase III VEGF Trap-Eye Trials.  // BioWorld Today;5/1/2009, Vol. 20 Issue 83, p2 

    The article reports on the plan of Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG to include central retinal vein occlusion (CRVO) in their global development program for Vascular Endothelial Growth Factor (VEGF) Trap-Eye. A Phase III program testing the efficacy and safety of VEGF...

  • Deals roundup.  // Medical Device Daily;8/16/2007, Vol. 11 Issue 156, p3 

    The article reports on the payment received by Regeneron Pharmaceuticals from Bayer HealthCare after dosing of the first patient in the Phase 3 study of the VEGF Trap-Eye in the neovascular form of age-related macular degeneration. According to Regeneron CEO Leonard S. Schleifer, results of...

  • BAYER/REGENERON EXTEND PROGRAM FOR VEGF TRAP-EYE.  // Worldwide Biotech;Jun2009, Vol. 21 Issue 6, p3 

    The article reports that Bayer Healthcare AG and Regeneron Pharmaceuticals have extended their development program for the investigational drug, vascular endothelial growth factor (VEGF) Trap-Eye, in June 2009. The phase three program will evaluate the efficiency and safety of the...

  • VEGF Trap undergoing global development.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p4 

    The article reports on the collaboration between Bayer Healthcare and Regeneron Pharmaceuticals Inc. in the U.S. The partnership was designed for the worldwide commercialized development of the vascular endothelial growth factor (VEGF) Trap for the potential treatment of the neovascular form of...

  • VEGF Trap Results Show VA Improvment in DME Patients.  // Review of Ophthalmology;Mar2010, Vol. 17 Issue 3, p4 

    The article reports on the study conducted by Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG that determines the efficacy of Vascular Endothelial Growth Factor (VEGF) Trap-Eye in the treatment for patients with diabetic macular edema. It states that the result of the study was met in...

  • Regeneron, Bayer Start Phase III With VEGF Trap-Eye In Wet AMD. Morrison, Trista // BioWorld Today;8/6/2007, Vol. 18 Issue 151, p1 

    The article reports on the pivotal procedure launched by Regeneron Pharmaceuticals Inc. and partner Bayer HealthCare AG for VEGF Trap-Eye with a Phase III trial comparing the drug to Lucentis (ranibizumab, Genentech Inc.) in wet age-related macular degeneration (wet AMD). The study is designed...

  • Regeneron and Bayer complete enrollment in two Phase III AMD trials.  // PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p12 

    The article reports that biopharmaceutical company Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG have finished patient enrollment in two Phase III clinical trials assessing vascular endothelial growth factor (VEGF) Trap-Eye in age-related macular degeneration (AMD) treatment. In each...

  • Company Showcase.  // Contract Pharma;Oct2010, Vol. 12 Issue 8, p114 

    The article offers information on several pharmaceutical companies in the U.S. It notes that Advantar Laboratories Inc. located in San Diego California has tools to accelerate product development. It mentions that Avema Pharma Solutions located in Miami Florida offers services related the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics